The opioid crisis has created an unprecedented challenge for many communities.
The opioid epidemic is killing more Americans than any other U.S. public health crisis in recent memory.
But many communities are struggling to get a handle on how to respond to the crisis.
The opioid crisis is not a problem of bad apples.
It is a problem that is being caused by the policies and practices of our country’s largest pharmaceutical companies.
This is not an epidemic of bad actors.
It’s an epidemic created by the actions of individuals, corporations and their corporate partners.
In recent years, drug companies have become more and more involved in health care.
With the help of the pharmaceutical industry, drug manufacturers have been able to create a new class of drugs, called “preclinical” drugs.
Preclinical drugs are not approved by the FDA to treat human disease.
Rather, they are used for the first time for clinical testing and testing to evaluate safety and efficacy.
These drugs have proven highly promising, but the drugs have also created a number of problems.
In 2016, the FDA approved the first opioid drug, OxyContin, for use in treating pain.
But the approval was not widely supported.
A large study in the United States found that the drug was associated with serious side effects, including addiction, psychosis, and death.
The pharmaceutical industry responded to the problem by aggressively lobbying Congress to make it easier for the FDA and the Centers for Disease Control and Prevention (CDC) to approve new drugs for the United State.
They sought to make these drugs available to patients for free, even though they were not approved for human use.
The federal government is still working to figure out what the future holds for the drugs that are available to the public.
The U.K., Canada, Australia, and Germany have all approved drugs for use on their own.
But these drugs have not always been widely used.
In 2017, the drug companies fought hard to keep their drugs from being used in the U.N. World Health Organization’s global opioid control program.
The pharmaceutical companies argued that these drugs would not be available to treat chronic pain in the developing world because the drugs were only used in countries that had not fully implemented a national system for opioid control.
The companies argued against using these drugs because of their limited benefits and because the U,S.
and other countries had not done enough to prevent the spread of drug-resistant bacteria.
This is why there are so many people in the world who are dying every day because of these opioid-resistant strains.
In the United Kingdom, for example, one in every three deaths is due to drug-resistance, according to the British Royal College of Psychiatrists.
The United States is also experiencing a large opioid epidemic, but not due to the pharmaceutical companies, as the Trump administration has said.
Instead, the opioid epidemic was caused by a series of corporate decisions.
The drug companies, in turn, have made a number to push their drugs onto the market.
The Drug Enforcement Administration (DEA) recently announced that they would begin to approve more generic versions of OxyContin and other opioid drugs, as well as a drug for treating severe depression.
These actions have put millions of Americans at risk of becoming addicted to opioid drugs and dying.
For decades, Americans have been told that addiction is a disease that can be treated.
But now, millions of people are suffering from an opioid epidemic that could kill them in their sleep.